CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS
Follicular lymphoma is the second most diagnosed lymphoma in Western Europe. Significant advancements have considerably improved the survival of FL patients. However, 10-20% of these patients are refractory to standard treatments, and most of them will relapse. The treatment of follicular lymphoma...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2024-01-01
|
Series: | Mediterranean Journal of Hematology and Infectious Diseases |
Subjects: | |
Online Access: | https://mjhid.org/mjhid/article/view/5577 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832544441303302144 |
---|---|
author | Ugo Testa Francesco D'Alò Elvira Pelosi Germana Castelli Giuseppe Leone |
author_facet | Ugo Testa Francesco D'Alò Elvira Pelosi Germana Castelli Giuseppe Leone |
author_sort | Ugo Testa |
collection | DOAJ |
description |
Follicular lymphoma is the second most diagnosed lymphoma in Western Europe. Significant advancements have considerably improved the survival of FL patients. However, 10-20% of these patients are refractory to standard treatments, and most of them will relapse. The treatment of follicular lymphoma patients with multiply relapsed or refractory disease represents an area of high-unmet needing new treatments with stronger efficacy. Chimeric antigen receptor (CAR)-T cell therapy targeting B-cell antigens, such as CD19 or CD20, is emerging as an efficacious treatment for R/R follicular lymphoma patients, particularly for those with early relapse and refractory to alkylating agents and to anti-CD20 monoclonal antibodies, resulting in a high rate of durable responses in a high proportion of patients.
|
format | Article |
id | doaj-art-e0180e0da7274c5e971c73ca2e54ce9c |
institution | Kabale University |
issn | 2035-3006 |
language | English |
publishDate | 2024-01-01 |
publisher | PAGEPress Publications |
record_format | Article |
series | Mediterranean Journal of Hematology and Infectious Diseases |
spelling | doaj-art-e0180e0da7274c5e971c73ca2e54ce9c2025-02-03T10:29:30ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062024-01-0116110.4084/MJHID.2024.012CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMASUgo Testa0Francesco D'Alò1Elvira Pelosi2Germana Castelli3Giuseppe Leone4Istituto Superiore Sanità, RomeUniversità Cattolica; Policlinico Gemelli, RomeIstituto Superiore Sanità, RomeIstituto Superiore Sanità, RomeUniversità Cattolica; Policlinico Gemelli, Rome Follicular lymphoma is the second most diagnosed lymphoma in Western Europe. Significant advancements have considerably improved the survival of FL patients. However, 10-20% of these patients are refractory to standard treatments, and most of them will relapse. The treatment of follicular lymphoma patients with multiply relapsed or refractory disease represents an area of high-unmet needing new treatments with stronger efficacy. Chimeric antigen receptor (CAR)-T cell therapy targeting B-cell antigens, such as CD19 or CD20, is emerging as an efficacious treatment for R/R follicular lymphoma patients, particularly for those with early relapse and refractory to alkylating agents and to anti-CD20 monoclonal antibodies, resulting in a high rate of durable responses in a high proportion of patients. https://mjhid.org/mjhid/article/view/5577Follicular LymphomaCAR-TImmunotherapy |
spellingShingle | Ugo Testa Francesco D'Alò Elvira Pelosi Germana Castelli Giuseppe Leone CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS Mediterranean Journal of Hematology and Infectious Diseases Follicular Lymphoma CAR-T Immunotherapy |
title | CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS |
title_full | CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS |
title_fullStr | CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS |
title_full_unstemmed | CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS |
title_short | CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS |
title_sort | car t cell therapy for follicular lymphomas |
topic | Follicular Lymphoma CAR-T Immunotherapy |
url | https://mjhid.org/mjhid/article/view/5577 |
work_keys_str_mv | AT ugotesta cartcelltherapyforfollicularlymphomas AT francescodalo cartcelltherapyforfollicularlymphomas AT elvirapelosi cartcelltherapyforfollicularlymphomas AT germanacastelli cartcelltherapyforfollicularlymphomas AT giuseppeleone cartcelltherapyforfollicularlymphomas |